Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study

• DOI: 10.1200/jco.2007.11.6525
• Publication Date: 2007-07-24T01:18:26Z
• Authors: Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raim...; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
• Keywords: ABVD; Dacarbazine; Univariate analysis; B symptoms; Progression-free survival

Starting from November 2001, 260 newly diagnosed patients with Hodgkin's lymphoma (HL) were consecutively enrolled in parallel Italian and Danish prospective trials to evaluate the prognostic role of an early interim 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan International Prognostic Score (IPS) advanced HL, treated conventional ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) therapy.Most (n = 190) presented disease (stages IIB through IVB), whereas 70 stage IIA adverse factors. All but 11 standard therapy followed by consolidation radiotherapy case bulky presentation or residual tumor mass. Conventional radiologic staging was performed at baseline. FDG-PET baseline after two courses (PET-2). No treatment change allowed on basis PET-2 results.After a median follow-up 2.19 years (range, 0.32 5.18 years), 205 continued complete remission partial remission. Forty-three progressed during immediately after, 10 relapsed. The 2-year progression-free survival for positive results 12.8% negative 95.0% (P < .0001). In univariate analysis, outcome significantly associated .0001), IV WBC more than 15,000 lymphopenia .001), IPS as continuous variable extranodal involvement .012). multivariate analyses, only turned out be significant .0001).PET-2 overshadows value emerges single most important tool planning risk-adapted HL.